EUCTR2017-005075-91-DK进行中(未招募)1 期
OW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM - STRATIFY
Copenhagen University Hospital Rigshospitalet0 个研究点目标入组 210 人开始时间: 2018年5月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Age = 18 years
- •2)Informed consent for trial participation
- •3)Intermediate high-risk PE according to ESC criteria
- •4)Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography
- •5)14 days of symptoms or less
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1)Altered mental state (GCS < 14)
- •2)No qualifying CT angiography performed (> 24 hour since CT angiography)
- •3)Females of child bearing potential, unless negative HCG test is present
- •4)Thrombolysis for PE within 14 days of randomization
- •5)Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)
- •6)Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)
- •7)Comorbidity making 6 months survival unlikely
- •8)Absolute contraindications for thrombolysis
- •a.Hemorrhagic stroke or stroke of unknown origin at any time
- •b.Ischemic stroke in the preceding 6 months
- •c.Central nervous system damage or neoplasms
- •d.Recent major trauma/surgery/head injury in the preceding 3 weeks
- •e. Gastrointestinal bleeding within the last month
- •f.Known bleeding risk
- •Relative contraindications do not preclude randomization. Relative contraindications include: Transient ischemic attack in the preceding 6 months, Oral anticoagulant therapy, Pregnancy, or within one week pPost partum, Non-compressible puncture site, Traumatic resuscitation, Refractory hypertension (systolic blood pressure >180 mm Hg), Advanced liver disease, Infective endocarditis, Active peptic ulcer
研究者
相似试验
尚未招募
不适用
IV THROMBOLYSIS(rt PA-Alteplase) AS TREATMEANT IN SEVERE COVID ARDSCTRI/2021/08/035445COLUMBIA ASIA REFERRAL HOSITA
已完成
不适用
Thromboelastometry Guided Blood-Component Therapy After Cardiac Surgery: A Randomized StudyT81.0D68.4Haemorrhage and haematoma complicating a procedure, not elsewhere classifiedAcquired coagulation factor deficiencyDRKS00017367Herzzentrum Universität Leipzig104
招募中
不适用
Safety and Efficacy of sonolysis therapy for treatment of microvascular damage after myocardial infarctioMyocardial infarctionHartinfarctNL-OMON28497VU University Medical Center20
进行中(未招募)
不适用
OR-SASS is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial, designed to establish the superiority of contrast-enhanced sonothrombolysis given within 4½ hours after stroke onset in consecutively admitted patients with acute ischaemic stroke, as compared with 1) standard iv thrombolysis with tenecteplase (TNK) or alteplase (tPA), and 2) no specific treatment in patients not eligible for thrombolytic treatment.All patients found eligible for thrombolysis may enter the thrombolysis-arm (NOR-SASS I), all patientswith contraindications to thrombolysis within the 4 ½ hour time window may enter the no-thrombolysis-arm(NOR-SASS II).MedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000323-41-NOHelse Bergen, Haukeland University Hospital
尚未招募
不适用
Bedside clotting study (Thromboelastography) for critical decision making in patients requiring massive blood transfusion at trauma centre.CTRI/2022/04/042334ICMR
